Credit Suisse analyst Martin Auster lowered his price target for Sarepta to $201 from $207 after the company received surprise CRL for Vyondys 53, with FDA citing the risk of infections related to the intravenous infusion ports and renal toxicity seen in preclinical models and observed following administration of other antisense oligonucleotides. The analyst says that both of these findings on the surface appear to be "a bit surprising" considering the severity of DMD and lack of treatment options for boys amenable to exon 53 skipping. Auster reiterates an Outperform rating on the shares.